Company Overview - Aspira Women's Health Inc. is focused on developing gynecologic disease diagnostic tools and has expanded its senior management team with the addition of Dr. Sandra Milligan as President effective April 1, 2024 [1][2] - The company has promoted Dr. Todd Pappas to lead the product development team following the departure of Dr. Jody Berry [1][4] Leadership Changes - Dr. Milligan brings over 25 years of experience in the healthcare sector, having held executive roles at biopharmaceutical companies such as Amgen, Genentech, Merck, and Organon [2] - As President, Dr. Milligan will oversee Research and Development, Operations, Information Technology, and Human Resources, with a focus on accelerating product launches and identifying partnerships [2][3] Product Development Focus - Dr. Pappas, who has been with Aspira since 2013, will continue to manage all aspects of scientific and product development, including relationships with academic partners [4] - The company is dedicated to enhancing outcomes for women suffering from gynecologic diseases, with a pipeline that includes advanced diagnostic tools for ovarian cancer and endometriosis [3][6] Diagnostic Tools and Pipeline - Aspira offers OvaWatch® and Ova1Plus® as part of the OvaSuiteSM, which provides comprehensive blood tests for ovarian cancer detection [5] - The company is developing OvaMDxSM and EndoCheckSM, aimed at improving noninvasive diagnostics for ovarian cancer and endometriosis, respectively [6]

Hi-Precision Laboratories, one of the largest medical laboratories in the Philippines, signs a 5-year OvaSuitSM commercial distribution agreement AUSTIN, Texas, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or "the Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the signing of a 5-year distribution agreement granting Hi-Precision Laboratories the exclusive right to market and di ...

AUSTIN, Texas, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has entered into definitive agreements with a single healthcare focused institutional investor alongside participation from Nicole Sandford, CEO of Aspira, as well as certain existing shareholders of the Company for the purchase and sale of 1,571,000 share ...

WALTHAM, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, is pleased to announce changes to its Board of Directors reflecting a strategic move to further align with the company's growth plans. After nearly a decade of service, Gus Halas is retiring from his position as Chairperson of the Board. During his tenure, he playe ...

Aspira Women's Health Inc. (NASDAQ:AWH) Q3 2023 Earnings Call November 13, 2023 4:30 PM ET Company Participants Nicole Sandford - President and Chief Executive Officer Torsten Hombeck - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Good afternoon, ladies and gentlemen, and welcome to the Aspira Women's Health Incorporated Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared ...

Financial Performance - Total revenue for the three months ended September 30, 2023, was $2,217,000, compared to $2,072,000 for the same period in 2022, representing an increase of 7%[12] - For the nine months ended September 30, 2023, total revenue reached $7,024,000, up from $6,031,000 in 2022, marking a growth of 16%[12] - Gross profit for the three months ended September 30, 2023, was $1,307,000, compared to $1,156,000 in the prior year, reflecting a 13% increase[12] - The net loss for the three months ended September 30, 2023, was $4,706,000, compared to a net loss of $7,783,000 for the same period in 2022, a decrease of 40%[12] - For the nine months ended September 30, 2023, the company reported a net loss of $13,601,000 compared to a net loss of $25,294,000 for the same period in 2022[21] Operating Expenses - Operating expenses for the three months ended September 30, 2023, totaled $5,423,000, down from $9,736,000 in the same period last year, a reduction of 44%[12] - Research and development expenses for the three months ended September 30, 2023, were $998,000, significantly lower than $2,157,000 in the same period last year, a reduction of 54%[12] - Sales and marketing expenses for the three months ended September 30, 2023, were $1,702,000, down from $3,950,000, a reduction of 57%[12] - General and administrative expenses for the three months ended September 30, 2023, were $2,723,000, compared to $3,629,000 in the prior year, a decrease of 25%[12] Cash Flow and Liquidity - The company incurred cash used in operating activities of $12,444,000 for the nine months ended September 30, 2023, down from $23,992,000 in the prior year[21] - As of September 30, 2023, the company had cash and cash equivalents of approximately $5,100,000, with an accumulated deficit of approximately $515,214,000[28] - The company expects to continue incurring net losses and negative cash flows from operations for the remainder of 2023[28] - The company has taken measures to protect its liquidity position, including potential capital raising and cost reduction strategies[28] Stock and Equity - The company issued 1,694,820 common shares under a registered direct offering, netting $4,157,000 after issuance costs[14] - The company has outstanding warrants to purchase shares of its common stock, although there is no assurance that these warrants will be exercised[29] - The company increased its authorized shares from 150,000,000 to 200,000,000 on February 6, 2023[99] - The company recorded stock-based compensation expense of $479,000 for the three months ended September 30, 2023, compared to $508,000 for the same period in 2022, a decrease of 5.7%[132] Compliance and Regulatory - The company regained compliance with Nasdaq listing requirements as of September 12, 2023, after previously receiving deficiency letters[32] - The company adopted new accounting standards related to credit losses and financial instruments, which did not have a material impact on its financial position[64][65] Errors and Restatements - The company identified a material error in its accounting for warrants, resulting in a restatement of financial statements for the year ended December 31, 2022, with a difference of approximately $3,768,000 in the fair value of the warrant liability[41] - The restatement of financial statements for the year ended December 31, 2022, and the interim financial statements for the three and nine months ended September 30, 2022, was necessary to reflect the correction of the error[44] Revenue Recognition - The company recognized approximately $5,000 and $115,000 in additional revenue for amounts collected in excess of revenue estimated for prior periods during the three and nine months ended September 30, 2023[37] - The company recognized product revenue upon completion of the OvaSuite test and delivery of results, based on estimates that require significant management judgment[36] Debt and Financing - The Company entered into a DECD Loan Agreement allowing borrowing up to $4,000,000 at a fixed interest rate of 2.0% per annum, with maturity on April 15, 2026[76] - The Company received a Paycheck Protection Program loan of approximately $1,006,000, which was confirmed for forgiveness in May 2021[75] Research and Development - The Company has incurred approximately $931,000 in research and development expenses related to the Dana-Faber, Brigham, Lodz Research Agreement since its inception[93] - Research and development expenses for the three months ended September 30, 2023, were $70,000, compared to $31,000 for the same period in 2022, an increase of 125.8%[132]

Aspira Women’s Health Inc. (NASDAQ:AWH) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Nicole Sandford – President and Chief Executive Officer Torsten Hombeck – Chief Financial Officer Conference Call Participants Sally Yanchus – Water Tower Research Andrew Brackmann – William Blair Operator Good afternoon, ladies and gentlemen, and welcome to Aspira’s Women’s Health, Incorporated Second Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-onl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-34810 Aspira Women's Health Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | |----- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-34810 Aspira Women's Health Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | |---- ...

Aspira Women's Health Inc. (NASDAQ:AWH) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Nicole Sandford - President and Chief Executive Officer Ryan Phan - Chief Scientific Officer and Chief Operating Officer Marlene McLennan - Interim Chief Financial Officer Conference Call Participants Sally Yanchus - Water Tower Research Operator Good afternoon ladies and gentlemen and welcome to Aspira Women's Health, Incorporated First Quarter 2023 Earnings Conference Call. During the pres ...